about
The South African child death review pilot: A multiagency approach to strengthen healthcare and protection for children.Missed opportunities for timely diagnosis of pediatric lupus in South Africa: a qualitative study.CANDLE Syndrome: orodfacial manifestations and dental implications.Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaborationJuvenile idiopathic arthritis in two tertiary centres in the Western Cape, South AfricaGain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling.HIV-associated juvenile systemic sclerosis: a case report.Impact of revascularization on hypertension in children with Takayasu's arteritis-induced renal artery stenosis: a 21-year review.A Review and Proposed Approach to the Neutrophilic Dermatoses of Childhood.Juvenile idiopathic arthritis–an update on its diagnosis and management.Child deaths in South Africa: Lessons from the child death review pilot.Fibrodysplasia ossificans progressiva in South Africa: difficulties in management in a developing country.Fibrodysplasia ossificans progressiva (FOP) in South Africa: dental implications in 5 cases.The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva.Infective dermatitis associated with human T-cell lymphotropic virus type 1 in a child with bronchiectasis.PW03-022 – Neutrophilic skin disease and inflammation.The spectrum of paediatric rheumatic diseases in two tertiary centres in Cape Town, South Africa.PReS-FINAL-2268: Sarcoidosis in children seen at the pediatric rheumatology clinics of two referral hospitals in Cape Town, South Africa.Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.Paediatric rheumatology in sub-Saharan Africa.Treating juvenile idiopathic arthritis to target: recommendations of an international task force.The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).A clinical update on paediatric lupus.PReS-FINAL-2253: A case series of HIV arthropathy in Cape Town.PReS-FINAL-2365: Southern hemisphere educational partnership for pediatric arthritis and rheumatological diseases (Sheppard): pediatric rheumatology without borders.PReS-FINAL-2366: Paediatric rheumatology in South Africa.MyastheniaGravis(MG) in a patient with Juvenile Idiopathic Arthritis.Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulationProceedings of the 23rd Paediatric Rheumatology European Society Congress: part oneSpecial Considerations for Clinical Trials in Fibrodysplasia Ossificans Progressiva (FOP)Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus CohortA Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activityFOP in South Africa: awareness leads to diagnosisJuvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South AfricaBudd-Chiari syndrome as presenting symptom of hepatic sarcoidosis in a child, with recurrence after liver transplantationPediatric systemic lupus erythematosus patients in South Africa have high prevalence and severity of cardiac and vascular manifestationsJuvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of HumankindChild health, infant formula funding and South African health professionals: Eliminating conflict of interestDistinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseasesSerious adverse drug reactions at two children's hospitals in South Africa
P50
Q30061962-40535743-F81D-476F-8907-19EBEF02D188Q30839806-AD55CCDB-0B90-4E16-BB0B-D05B82FAA2D4Q34506796-9413C20E-6958-4A05-A1B5-607C11EE3D7EQ35102471-22B5CBA2-5000-4DFC-8403-81CEDBF7937AQ36552319-BAAD8445-7CB5-455E-A390-298580F7B200Q37732141-48E26290-FD69-4C22-A869-650DDAF4E997Q38253269-0408C4A7-110F-4C61-9DD9-CC22BDDA1876Q38343154-2AC0D3BE-1CA4-452E-BC57-8863FEFA2A09Q38366349-4D19E542-2AA2-4FDA-87BC-8F8FF0A7E695Q38757630-937DE719-3710-4E39-9D88-501DDF8A63C3Q38947907-4CE66F27-C9F3-4E9F-82E7-D610206BCA9BQ39963495-022CB2E9-E916-4062-A4F0-8C205F4378FCQ39986953-1DC08ED6-3D3E-4568-9B10-817BDF998E59Q42687491-1D1AFA1E-B32C-4773-A416-ADFCDB21D9A5Q45352941-6580A255-1AFB-4E18-A18C-2D0F7DA2718DQ46052440-2B48EF99-18CC-4B9B-8F53-DBC0E2FC8B93Q46965263-1CD5E816-F283-4662-AED2-98D1D51C4A2DQ47132246-6ADC7357-5E82-4703-A414-ED5751E1D59CQ50231899-EDCC78FD-F873-435B-A126-8C9518D4400BQ50480787-CD10C001-8DCC-4650-B6E1-6F7B267B3ADBQ52593303-F9141B72-B9AA-4D66-959A-6FD312C2302CQ52594864-8EB54F86-88D9-4D21-A4D6-B624B59FC646Q53770441-5453B2A5-1521-4398-80FB-FD13840AF94BQ55527763-A4CD9393-7F2D-4CFD-8C51-5513F19CB67CQ55527882-9DC2602B-F412-4B2C-861A-B31CE8E8CEABQ55537158-E91C6D54-FFE1-4746-A1C6-83E16D78764EQ55611167-D79A6CA8-1C0C-48B1-AF4F-F202AE304EAFQ56923869-AD9133B1-A1DF-4C52-981A-044E062B905AQ56957893-24F13B20-4278-4066-ADF0-5D8D2D006946Q57034853-A8FAC846-FFAA-40A3-BF51-CE970081F798Q57804441-DB2091F0-FFC8-4BC0-A12A-4B46B4C6A19DQ58548284-90658B1F-551F-495D-99A5-41208E22B2A6Q59268756-8FD0367F-6805-4146-AD00-EFEF43833C66Q59268802-1FDAD871-6696-4C3B-A795-5A6E7F515FA2Q82247648-C53FE614-16BA-4034-9B98-55F0C1C76D86Q91470928-01B96212-5D9E-410A-8360-6AC257403DB9Q91864189-F9286D51-EF72-47E2-8A09-22A808A51F8DQ92182441-F12BF709-8AC0-4D3F-BBD0-65C52E1C3876Q92234375-2DB4A519-BFFA-4B03-A109-E30DE91FFEDCQ92413057-E7726EC6-BEAD-45EF-B54B-0C62BD6D36AB
P50
description
medical researcher, ORCID id # 0000-0003-3874-1704
@en
onderzoeker
@nl
name
Chris Scott
@ast
Chris Scott
@en
Chris Scott
@es
Chris Scott
@nl
type
label
Chris Scott
@ast
Chris Scott
@en
Chris Scott
@es
Chris Scott
@nl
prefLabel
Chris Scott
@ast
Chris Scott
@en
Chris Scott
@es
Chris Scott
@nl
P106
P1153
36773492800
P31
P496
0000-0003-3874-1704